Compare abrdn Physical Palladium Shares ETF (PALL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Physical Palladium Shares ETF vs Viatris Inc — how do they compare? abrdn Physical Palladium Shares ETF trades at $20.77 (market cap $586.03M), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 34.2× abrdn Physical Palladium Shares ETF's market cap, and Viatris Inc pays a 2.75% dividend while abrdn Physical Palladium Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold abrdn Physical Palladium Shares ETF for 33 Days and Viatris Inc for 57 Days on average.
| PALL | VTRS | |
|---|---|---|
Market Cap | $586.03M | $20.03B |
Volume | 1,257,028 | 14,109,977 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.18 | $18.27 |
52-Week Low | $20.30 | $9.74 |
Typical Hold Time | 33 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PALL trades at $20.49, up 0.94% today, but technical indicators signal a bearish trend with moving averages unanimously negative. Recent news highlights palladium's underperformance versus other precious metals, with some analysts viewing current price weakness as a buying opportunity due to supply risks and industrial demand potential. Financial ratios are unavailable, limiting fundamental assessment.
The outlook remains cautious; while oversold RSI levels suggest potential for a rebound, bearish momentum dominates. Key risks include commodity price volatility and reliance on industrial demand. Investors should weigh technical weakness against contrarian bullish arguments from recent analyst coverage.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
